Amit C. Achhra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amit C. Achhra has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Janaki Amin
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia
3 shared publications David A Cooper
National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, UNSW, Sydney, Australia
1 shared publication- David James Templeton
Kirby Institute, University of New South Wales, Sydney, Australia
1 shared publication Fred M Gordin
Veterans Affairs Medical Center, Washington DC and George Washington University School of Medicine
1 shared publicationFujie Zhang
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Yunnan, People's Republic of China
1 shared publication- Ian Woolley
Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
1 shared publication
Latest Publications
- 1 July 2011
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 6 (4) , 258-265
Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries
To summarize the recent findings on long-term (at least 3-4 years) immunological responses to combination antiretroviral therapy (cART) and to compare and contrast the findings between cohorts from high-income and low-middle income countries (LMICs). Cohort studies from high-income settings suggest that a majority of treated HIV-infected patients who maintain suppressed HIV viremia experience a gradual increase in CD4 cell counts for several years to normal levels. However, those who start cART at CD4 cell counts less than 200 cells/μl (as opposed to CD4 cell counts>200 cells/μl) spend several more years below the safe CD4 cell count threshold of 500 cells/μl. Cohorts from LMICs also report persistent improvements in CD4+ cell counts over first 4-5 years of follow-up. However, low-CD4 cell counts (<200 cells/μl) at the start of cART, high early mortality, and loss to follow-up in LMICs settings suggest that the observed optimistic responses may be affected by survivorship bias and should be cautiously interpreted as the optimal, rather than an average, response in LMICs populations. LMICs cohorts report similar immunological responses to cART as high-income countries in first 4-5 years of follow-up. Sustaining success in these settings is dependent on timely access to first-line and future cART options, efforts to reduce loss to follow-up, and implementation of treatment guidelines. Cohorts from LMICs are encouraged to continue improving treatment programs and to continue reporting outcomes over the next decade, as surveillance for potential future blunting in responses.
- 1 July 2011
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 6 (4) , 258-265
Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries
To summarize the recent findings on long-term (at least 3-4 years) immunological responses to combination antiretroviral therapy (cART) and to compare and contrast the findings between cohorts from high-income and low-middle income countries (LMICs). Cohort studies from high-income settings suggest that a majority of treated HIV-infected patients who maintain suppressed HIV viremia experience a gradual increase in CD4 cell counts for several years to normal levels. However, those who start cART at CD4 cell counts less than 200 cells/μl (as opposed to CD4 cell counts>200 cells/μl) spend several more years below the safe CD4 cell count threshold of 500 cells/μl. Cohorts from LMICs also report persistent improvements in CD4+ cell counts over first 4-5 years of follow-up. However, low-CD4 cell counts (<200 cells/μl) at the start of cART, high early mortality, and loss to follow-up in LMICs settings suggest that the observed optimistic responses may be affected by survivorship bias and should be cautiously interpreted as the optimal, rather than an average, response in LMICs populations. LMICs cohorts report similar immunological responses to cART as high-income countries in first 4-5 years of follow-up. Sustaining success in these settings is dependent on timely access to first-line and future cART options, efforts to reduce loss to follow-up, and implementation of treatment guidelines. Cohorts from LMICs are encouraged to continue improving treatment programs and to continue reporting outcomes over the next decade, as surveillance for potential future blunting in responses.
- Open Access
- 20 April 2011
- Published by SAGE Publications in Journal of the International Association of Physicians in AIDS Care
- Vol. 10 (3) , 160-170
The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD
The significance of interethnic variation in CD4 counts between Asian and Caucasian populations is not known. Patients on combination antiretroviral therapy from Treat Asia and Australian HIV Observational Databases (TAHOD, predominantly Asian, n = 3356; and AHOD, predominantly Caucasian, n = 2312, respectively) were followed for 23 144 person-years for AIDS/death and all-cause mortality endpoints. We calculated incidence-rates and used adjusted Cox regression to test for the interaction between cohort (TAHOD/AHOD) and time-updated CD4 count category (lagged by 3 months) for each of the endpoints. There were 382 AIDS/death events in TAHOD (rate: 4.06, 95%CI: 3.68-4.50) and 305 in AHOD (rate: 2.39, 95%CI: 2.13-2.67), per 100 person-years. At any given CD4 count category, the incidence-rates of endpoints were found to be similar between TAHOD and AHOD (in the adjusted models, P > .05 for the interaction term between cohort type and latest CD4 counts). At any given CD4 count, risk of AIDS or death was not found to vary by ethnicity, suggesting that the CD4 count thresholds for predicting outcomes defined in Caucasian populations may be equally valid in Asian populations.
- 20 April 2011
- Published by SAGE Publications in Journal of the International Association of Physicians in AIDS Care
- Vol. 10 (3) , 160-170
Open AccessThe Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD
The significance of interethnic variation in CD4 counts between Asian and Caucasian populations is not known. Patients on combination antiretroviral therapy from Treat Asia and Australian HIV Observational Databases (TAHOD, predominantly Asian, n = 3356; and AHOD, predominantly Caucasian, n = 2312, respectively) were followed for 23 144 person-years for AIDS/death and all-cause mortality endpoints. We calculated incidence-rates and used adjusted Cox regression to test for the interaction between cohort (TAHOD/AHOD) and time-updated CD4 count category (lagged by 3 months) for each of the endpoints. There were 382 AIDS/death events in TAHOD (rate: 4.06, 95%CI: 3.68-4.50) and 305 in AHOD (rate: 2.39, 95%CI: 2.13-2.67), per 100 person-years. At any given CD4 count category, the incidence-rates of endpoints were found to be similar between TAHOD and AHOD (in the adjusted models, P > .05 for the interaction term between cohort type and latest CD4 counts). At any given CD4 count, risk of AIDS or death was not found to vary by ethnicity, suggesting that the CD4 count thresholds for predicting outcomes defined in Caucasian populations may be equally valid in Asian populations.
- 31 July 2010
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (12) , 1877-1886
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients
Objective: To investigate the relative predictive value of CD4+ metrics for serious clinical endpoints. Design: Observational. Methods: Patients (3012; 20 317 person-years) from control arms of ESPRIT and SILCAAT were followed prospectively. We used Cox regression to identify CD4+ metrics (latest, baseline and nadir CD4+ cell count, latest CD4+%, time spent with CD4+ count below certain thresholds and CD4+ slopes) independently predictive of all-cause mortality, non-AIDS deaths, non-AIDS (cardiovascular, hepatic, renal and non-AIDS malignancy) and AIDS events. Akaike information criteria (AIC) were calculated for each model. Significant metrics (P < 0.05) were then additionally adjusted for latest CD4+ cell count. Results: Non-AIDS deaths occurred at a higher rate than AIDS deaths [rate ratio: 6.48, 95% confidence interval (CI) 5.1–8.1], and non-AIDS events likewise (rate ratio: 1.72, 95% CI 1.65–1.79). Latest CD4+ cell count was strongly predictive of lower risk of death (hazard ratio per log2 rise: 0.48, 95% CI 0.43–0.54), with lowest AIC of all metrics. CD4+ slope over seven visits, after additional adjustment for latest CD4+ cell count, was the only metric to be an independent predictor for all-cause (hazard ratio for slope <−10 cells/μl per month vs. 0 ± 10: 3.04, 95% CI 1.98–4.67) and non-AIDS deaths (hazard ratio for slope <−10 cells/μl per month vs. 0 ± 10: 2.62, 95% CI 1.62–4.22). Latest CD4+ cell count (per log2 rise) was the best predictor across all four endpoints and predicted hepatic (hazard ratio 0.46, 95% CI 0.33–0.63) and renal events (hazard ratio 0.39, 95% CI 0.21–0.70), but not cardiovascular events (hazard ratio 1.05, 95% CI 0.77–1.43) or non-AIDS cancers (hazard ratio 0.78, 95% CI 0.59–1.03). Conclusion: Latest CD4+ cell count is the best predictor of serious endpoints. CD4+ slope independently predicts all-cause and non-AIDS deaths.
- 31 July 2010
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (12) , 1877-1886
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients
Objective: To investigate the relative predictive value of CD4+ metrics for serious clinical endpoints. Design: Observational. Methods: Patients (3012; 20 317 person-years) from control arms of ESPRIT and SILCAAT were followed prospectively. We used Cox regression to identify CD4+ metrics (latest, baseline and nadir CD4+ cell count, latest CD4+%, time spent with CD4+ count below certain thresholds and CD4+ slopes) independently predictive of all-cause mortality, non-AIDS deaths, non-AIDS (cardiovascular, hepatic, renal and non-AIDS malignancy) and AIDS events. Akaike information criteria (AIC) were calculated for each model. Significant metrics (P < 0.05) were then additionally adjusted for latest CD4+ cell count. Results: Non-AIDS deaths occurred at a higher rate than AIDS deaths [rate ratio: 6.48, 95% confidence interval (CI) 5.1–8.1], and non-AIDS events likewise (rate ratio: 1.72, 95% CI 1.65–1.79). Latest CD4+ cell count was strongly predictive of lower risk of death (hazard ratio per log2 rise: 0.48, 95% CI 0.43–0.54), with lowest AIC of all metrics. CD4+ slope over seven visits, after additional adjustment for latest CD4+ cell count, was the only metric to be an independent predictor for all-cause (hazard ratio for slope <−10 cells/μl per month vs. 0 ± 10: 3.04, 95% CI 1.98–4.67) and non-AIDS deaths (hazard ratio for slope <−10 cells/μl per month vs. 0 ± 10: 2.62, 95% CI 1.62–4.22). Latest CD4+ cell count (per log2 rise) was the best predictor across all four endpoints and predicted hepatic (hazard ratio 0.46, 95% CI 0.33–0.63) and renal events (hazard ratio 0.39, 95% CI 0.21–0.70), but not cardiovascular events (hazard ratio 1.05, 95% CI 0.77–1.43) or non-AIDS cancers (hazard ratio 0.78, 95% CI 0.59–1.03). Conclusion: Latest CD4+ cell count is the best predictor of serious endpoints. CD4+ slope independently predicts all-cause and non-AIDS deaths.
- 1 August 2009
- Vol. 38 (8) , 605-8
Health promotion in Australian general practice: a gap in GP training.
General practitioners are well placed to provide health promotion, both at the individual level and more broadly by addressing socioenvironmental determinants of health. However, important barriers exist which need to be tackled. This article describes the current approach to health promotion by Australian GPs and identifies a gap in GP training and education as an important barrier to health promotion. Health promotion by Australian GPs is currently focused on the individual behaviour of patients. To improve the health of individuals, however, it is also vital to tackle the broader socioenvironmental determinants of health. One of the important barriers to a more holistic approach is a lack of understanding about the principles of health promotion among GPs, suggesting a significant gap in their training. Future research should focus on integrating health promotion into the medical curricula at the undergraduate, graduate and continuing medical education levels.
- 1 August 2009
- Vol. 38 (8) , 605-8
Health promotion in Australian general practice: a gap in GP training.
General practitioners are well placed to provide health promotion, both at the individual level and more broadly by addressing socioenvironmental determinants of health. However, important barriers exist which need to be tackled. This article describes the current approach to health promotion by Australian GPs and identifies a gap in GP training and education as an important barrier to health promotion. Health promotion by Australian GPs is currently focused on the individual behaviour of patients. To improve the health of individuals, however, it is also vital to tackle the broader socioenvironmental determinants of health. One of the important barriers to a more holistic approach is a lack of understanding about the principles of health promotion among GPs, suggesting a significant gap in their training. Future research should focus on integrating health promotion into the medical curricula at the undergraduate, graduate and continuing medical education levels.